Bioservo Q1’22: First take - Redeye

Redeye's first impressions on the Q1 report from Bioservo earlier this morning. The sales although small, were slightly better than expected. On the other hand, the cost levels were also higher, partly due to the cost of a non-recurring nature of an extensive commercial analysis for Carbonhand. Apart from this, the report does not show any significant surprises.

Länk till analysen i sin helhet: https://www.redeye.se/research/840372/bioservo-q122-first-take?utm_source=finwire&utm_medium=RSS